{"prompt": "['2017N331008_00', 'CONFIDENTIAL', '208090', 'must be clearly labelled with the subject number, protocol number, site/centre number,', 'and visit date. Details for the preparation and shipment of samples will be provided by', 'Q2 Solutions and are detailed in the laboratory manual. Reference ranges for all safety', 'parameters will be provided to the site by Q2 Solutions.', 'If additional non-protocol specified laboratory assessments are performed at the', \"institution's local laboratory and result in a change in participant management or\", 'are considered clinically significant by the investigator (e.g. SAE or AE or dose', 'modification) the results must be recorded in the eCRF. Please refer to', 'Appendix 14 in Section 11.14 for study management information during the', 'COVID-19 pandemic.', 'Labs will be graded automatically by the central lab according to the DAIDS', 'toxicity scales (See Section 11.11 \"Division of AIDS Table for Grading the', 'Severity of Adult and Pediatric Adverse Events\").', 'The investigator must review the laboratory report, document this review, and', 'record any clinically relevant changes occurring during the study in the AE', 'section of the eCRF. The laboratory reports must be filed with the source', 'documents. Clinically significant abnormal laboratory findings are those which', 'are not associated with the underlying disease, unless judged by the investigator', \"to be more severe than expected for the participant's condition.\", 'All laboratory tests with values considered clinically significantly abnormal', 'during participation in the study or within 5 days after the last dose of study', 'intervention should be repeated until the values return to normal or baseline or', 'are no longer considered significantly abnormal by the investigator or medical', 'monitor.', 'If such values do not return to normal/baseline within a period of time judged', 'reasonable by the investigator, the etiology should be identified and the sponsor', 'notified.', 'Refer to the SRM for appropriate processing and handling of samples to avoid', 'duplicate and/or additional blood draws.', 'Haematology, clinical chemistry, urinalysis and additional parameters to be', 'tested are listed in Section 11.7.', '8.2.5.', 'Suicidal Risk Monitoring', 'Participants with HIV infection occasionally may present with symptoms of depression', 'and/or suicidality (suicidal ideation or behaviour). In addition, there have been some', 'reports of depression, suicidal ideation and behaviour (particularly in people with a', 'pre-existing history of depression or psychiatric illness) in some people being treated', 'with INIs, including DTG. Therefore, it is appropriate to monitor participants for', 'suicidality before and during treatment.', 'Participants should be monitored appropriately and observed closely for suicidal ideation', 'and behaviour or any other unusual changes in behaviour. It is recommended that the', '61']['2017N331008_06', 'CONFIDENTIAL', '208090', 'investigator consider mental health consultation or referral for participants who', 'experience signs of suicidal ideation or behaviour. Participants presenting with new', 'onset/treatment emergent depression should be advised to contact the investigator', 'immediately if symptoms of severe acute depression (including suicidal', 'ideation/attempts) develop, because medical intervention and discontinuation of the study', 'medication may be required.', 'Assessment of treatment-emergent suicidality will be monitored during this study using', 'the electronic version of the Columbia Suicidality Severity Rating Scale (eC-SSRS). The', 'definitions of behavioural suicidal events used in this scale are based on those used in the', 'Columbia Suicide History Form [Posner, 2007]. Questions are asked on suicidal', 'behaviour, suicidal ideation, and intensity of ideation. Day 1 (Baseline) visit questions', 'will be in relation to lifetime experiences and current experiences (within the past', '2 months); all subsequent questioning is in relation to the last assessment. The eC-SSRS', 'is to be administered as a participant completed questionnaire specified in the SoA. The', 'eC-SSRS will be conducted electronically by telephone or by computer/tablet connected', 'to the internet.', 'Additionally, the investigator will collect information using the Possible Suicidality-', 'Related AE (PSRAE) eCRF form in addition to the AE (non-serious or SAE) eCRF form', 'on any participant that experiences a possible suicidality-related AE while participating', 'in this study. This may include, but is not limited to, an event that involves suicidal', 'ideation, a preparatory act toward imminent suicidal behaviour, a suicide attempt, or a', 'completed suicide. The investigator will exercise his or her medical and scientific', 'judgment in deciding whether an event is possibly suicide-related. PSRAE forms should', 'be completed and reported to ViiV/GSK within 1 week of the investigator diagnosing a', 'possible suicidality-related AE.', '8.2.6.', 'Pregnancy', 'Details of all pregnancies in female participants will be collected after the start of study', 'intervention and ending at the final Follow-up visit. If a pregnancy is reported, the', 'investigator should inform ViiV/GSK/PPD within 2 weeks of learning of the pregnancy', 'and should follow the procedures outlined in Section 11.4.3.', 'Any pregnancy that occurs during study participation must be reported using a clinical', 'trial pregnancy form. The pregnancy must be followed up to determine outcome', '(including premature termination) and status of mother and child(ren) Pregnancy', 'complications and elective terminations for medical reasons must be reported as an AE or', 'SAE. Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth,', 'congenital anomalies, ectopic pregnancy) are considered SAEs and must be reported.', \"Any SAE occurring in association with a pregnancy brought to the investigator's\", 'attention after the participant has completed the study and considered by the investigator', 'as possibly related to the study intervention must be reported promptly to ViiV/GSK (or', 'designee).', \"GSK's central safety department will forward this information to the ART Pregnancy\", 'Registry. The international registry is jointly sponsored by manufacturers or licensees of', '62']\n\n###\n\n", "completion": "END"}